This week, Asphalion participated in the kick-off meeting of a new EU H2020, the European funded projects, named In2sight, where we will be the regulatory partners through the development of the project. Our experts Marta Rayo Lunar, Oriol Penon and Luis Borges attended the meeting.
Routine clinical use of biomaterials requires the reduction of the economical and ethical costs of biocompatibility tests (ISO10993 EU norm) which are unsustainable for small-medium industries and for the society.
In this project, the goal is to foster an unprecedented breakthrough in in-vivo optical imaging that will radically renew the biocompatibility tests of biomaterials. This technology will recast our thinking of biomaterial validation, allowing unprecedented quantitative and longitudinal analyses of the host inflammatory response to the implant.
The project will allow unique quantification of the immune reaction to biomaterials at the cellular level (scientific impact), largely reducing the ethical burden of the research and the costs of biomaterial discovery (economic impact), and will Refine and Reduce protocols for biocompatibility on a single revolutionary device (regulatory impact).
Horizon 2020 is the biggest EU Research and Innovation program ever with nearly €80 billion of funding available over 7 years (2014 to 2020) It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.
For further information, you can contact us at: info@asphalion.com
You can read more about the project here:
